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Background: In Cystic Fibrosis (CF), the airways are often colonized by opportunistic
fungi. The most frequently detected mold is Aspergillus fumigatus (Af). Af diseases are
associated with significant morbidity and mortality. The most common clinical picture
caused by Af is allergic bronchopulmonary aspergillosis (ABPA), triggered by an
immunological reaction against Af. Af bronchitis and invasive aspergillosis rarely occur
in CF as a result of spore colonization and germination. Since pulmonary mycoses and
exacerbations by other pathogens overlap in clinical, radiological, and immunological
characteristics, diagnosis still remains a challenge. The search for reliable, widely available
biomarkers for Af diseases is therefore still an important task today.
Objectives: Af-specific IgG m3 is broadly available. Sensitivity and specificity data are
contradictory and differ depending on the study population. In our prospective study on
pulmonary Af diseases in CF, we determined specific IgG m3 in order to test its suitability
as a biomarker for acute Af diseases and as a follow-up parameter.
Methods: In this prospective single center study, 109 patients with CF were screened
from 2016 to 2019 for Af-associated diseases. According to diagnostic criteria, they were
divided into four groups (control, bronchitis, ABPA, pneumonia). The groups were
compared with respect to the level of Af-specific IgG (ImmunoCAP Gm3). We
performed a receiver operating characteristic (ROC) curve analysis to determine cut-off,
sensitivity and specificity. Twenty-one patients could be enrolled for a follow-up
examination.
Results:Of the 109 patients, 36 were classified as acute Af-disease (Af bronchitis, ABPA,
Af pneumonia). Of these, 21 patients completed follow up-screening. The median Af-
specific Gm3 was higher in the acute Af-disease groups. There was a significant difference
in Af-specific IgG m3 compared to the control group without acute Af-disease. Overall,
there was a large interindividual distribution of Gm3. A cut-off value of 78.05 mg/L for Gm3
was calculated to discriminate controls and patients with ABPA/pneumonia with a
specificity of 75% and a sensitivity of 74.6%. The follow up examination of 21 patients
showed a decrease of Gm3 in most patients without statistical significance due to the
small number of follow up patients.gy | www.frontiersin.org January 2021 | Volume 10 | Article 6028361
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Frontiers in Cellular and Infection MicrobioloConclusion: Af specific IgG may be a useful biomarker for acute ABPA
and Af pneumonia, but not for Af bronchitis in CF. However, due to the large
interindividual variability of Gm3, it should only be interpreted alongside other
biomarkers. Therefore, due to its broad availability, it could be suitable as a biomarker
for ABPA and Af pneumonia in CF, if the results can be supported by a larger multicenter
cohort.Keywords: cystic fibrosis, aspergillosis, Aspergillus fumigatus, allergic bronchopulmonary aspergillosis, ABPA,
Gm3, Aspergillus fumigatus-specific IgGINTRODUCTION
Cystic fibrosis (CF) is the most common lethal genetic disease in
Caucasians and affects approximately between 70,000 and
100,000 people worldwide. The leading cause of death is the
progressive lung disease, driven by a complex and diverse
inflammatory immune syndrome induced by recurrent and
chronic bacterial and fungal infections of the lung (Stephenson
et al., 2015; Bell et al., 2020).
A. fumigatus (Af), the most frequently detected mold fungus
in CF airways, is the fungal pathogen with the most impact on
morbidity and mortality in CF (Pihet et al., 2009; Amin et al.,
2010; Middleton et al., 2013; Schwarz et al., 2018a). The defective
chloride channel in CF together with impaired mucociliary
clearance and structural changes resulting from infectious
complications (e.g. cavitary lung disease, bronchiectasis) result
in a local mucosal immunodeficiency (Cohen and Prince, 2012),
which allows airway pathogens like Af conidia to colonize and
germinate in the airways. Allergic bronchopulmonary
aspergillosis (ABPA), bronchitis, aspergilloma and invasive
infection (pneumonia) are the known disease entities caused
by Af in CF (Moss, 2010; Baxter et al., 2013a; Middleton et al.,
2013; Hong et al., 2018).
ABPA is an immune mediated lung disease with a prevalence
of up to 15% in CF. It manifests with a poorly controlled
obstructive disease and recurrent pulmonary infiltrates with or
without bronchiectasis (Stevens, 2003). According to the 2003
CFF (Cystic Fibrosis Foundation) consensus criteria, classic
diagnosis of ABPA comprises clinical deterioration not
attributed to other causes, serum IgE >1000 IU/ml, a positive
skin prick test or positive specific IgE, antibodies against Af,
precipitating or IgG antibodies against Af, and radiological
changes that are not treatable by antibiotics. For the minimal
ABPA criteria, serum IgE >500 IU/ml and fewer of the criteria
mentioned above are sufficient to suspect ABPA (Stevens, 2003).
Invasive pulmonary Af infections primarily occur in severely
immunocompromised patients, but they also can occur in CF if
additional risk factors are present (e.g. severe lung disease,
diabetes, steroid therapy) (Kousha et al., 2011; Hong et al.,
2018). The prevalence is extremely low, thus precise data are
not available. In CF, invasive pulmonary Af infections often show
a subacute, slowly progressing clinical course. and is induced by
local invasion of Af (Schwarz et al., 2018b). Radiographic
imaging and clinical courses are often non-specific (Felton and
Simmonds, 2014; Kosmidis and Denning, 2015). This bears thegy | www.frontiersin.org 2risk of delayed diagnosis in CF. Af bronchitis is another Af
entity with an estimated prevalence of 9% in CF. Increasing
evidence exists that Af in CF can cause airway symptoms
without hypersensitivity and without tissue invasion of fungal
hyphae (Felton and Simmonds, 2014; Brandt et al., 2018).
Shoseyov et al. were the first to report on Af bronchitis in six
patients (Shoseyov et al., 2006). The group suggested that
bronchitis should be considered, and antifungal therapy
initiated when deteriorating respiratory function is not
responding to antibacterial therapy, Af is growing in sputum
cultures and ABPA was excluded. Chrdle et al. proposed a
definition using clinical criteria: symptomatic chronic lower
airway disease, detection of Af in sputum or bronchial alveolar
lavage (BAL) by culture or PCR, and detection of Aspergillus-
specific IgG antibodies (Chrdle et al., 2012). In summary,
repeatedly detected Af in sputum samples and persistent
respiratory symptoms without signs of Af hypersensitivity
and without radiographic evidence of infection are
characteristics of Af bronchitis in patients with CF
(Felton and Simmonds, 2014; Kosmidis and Denning, 2015).
Due to the polymicrobial colonization, overlapping clinical,
radiographic, and laboratory characteristics, it is still difficult
to clearly distinguish Af conditions from other causes of
bronchopulmonary exacerbation in CF (Stevens, 2003). This
bears the risk of Af diseases being missed and can lead to
situations in which a potentially harmful differential therapeutic
strategy must be attempted in order to achieve successful
treatment. Therefore, the search for reliable, widely available
biomarkers for Af diseases is still an important task today (el-
Dahr et al., 1994; Kurup, 2005; Latzin et al., 2008; Hafen GM
et al., 2009; Delhaes et al., 2010; Scheffold et al., 2018; Keown
et al., 2019). In this light, it seems useful to evaluate single
biomarkers in terms of their significance for Af diseases. Af IgG
antibodies are used for diagnosis of chronic pulmonary
aspergillosis (CPA) and aspergillus diseases in patients with
chronic lung disorders and are referred to as diagnostic criteria
in many guidelines (Stevens, 2003; Delhaes et al., 2010; Agarwal
et al., 2017). They are found in many patients with ABPA,
bronchitis and invasive aspergillosis, and several assays are
available. In the clinical routine, in recent years, technologies
like ImmunoCAP have continuously replaced older methods
like immunoprecipitation (Van Hoeyveld et al., 2006; Baxter
et al., 2013b). The ImmunoCAP technique provides
quantitative measures and reproducible results and therefore
a higher sensitivity and specificity in detecting aspergillusJanuary 2021 | Volume 10 | Article 602836
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standardization in terms of cut-off values, as several working
groups examining Af IgG in Af related conditions obtained
discrepant results, which is in part due to different study
designs and different laboratory methods used, but this may
also reflect the different host-pathogen-interaction of
heterogeneous study populations with different underlying
diseases (Agarwal et al., 2017; Sehgal et al., 2018; Alghamdi
et al., 2019; Sehgal et al., 2019). We therefore evaluated specific
Af IgG in ABPA, Af bronchitis and invasive aspergillosis in CF.MATERIALS AND METHODS
This prospective study was conducted between January 2016 and
December 2019 at Christiane Herzog Cystic Fibrosis Center,
Charité—Universitätsmedizin Berlin, Germany. Ethical aspects
were considered and approval for the study was gained by the
Ethics Committee of Charité—Universitätsmedizin Berlin,
Germany (Number EA2/121/16).
We collected sera from 109 patients with CF, ages 6–69 years,
independent of their history of Af related conditions. To obtain
both a control group and a disease group, Af-specific IgG was
determined either as part of a diagnostic workup
when Af conditions were suspected or without such suspicion
in pulmonary exacerbated and in clinically stable patients during
routine checkup. Af-specific IgG (ImmunoCAP Gm3) was
determined in our routine laboratory. Depending on the
diagnosis criteria for Af related conditions in CF, the patients
were categorized into four groups: control, Af bronchitis, ABPA,
and Af pneumonia. As a few patients were assessed several times
during the course of the study, some follow-up measurements for
Gm3 are available and listed below.
Diagnosis Criteria for Af Related
Conditions
Diagnosis of ABPA was based on the minimal 2003 Cystic
Fibrosis Foundation (CFF) consensus criteria: i) serum IgE
>500 IU/ml; ii) Af-specific IgE >0.35 kU/L; iii) clinical
deterioration not attributed to other causes; and one of the
following criteria: i) presence of Af IgG (Gm3 ImmunoCAP)
antibodies in serum; ii) new or recent abnormalities on chest
radiography or chest CT that have not cleared with antibiotics
and standard physiotherapy. In one patient, diagnosis of ABPA
was assumed despite a total IgE <500 kU/L due to a threefold
increase in total IgE and positive diagnosis criteria.
Af bronchitis was defined as: i) clinical deterioration with
repeatedly positive sputum and Af PCR or repeatedly positive
sputum cultures (≥2 during the past 6 months) for Af, ii) no
antibiotic treatment response, iii) total serum IgE level <200 kU/
L, iv) no observation of new pulmonary infiltrates, and v)
appropriate antifungal treatment response.
Criteria for diagnosis of Af pneumonia were i) positive
sputum Af PCR or repeatedly positive sputum cultures for
Af, ii) new or recent abnormalities on chest radiography or
chest CT that have not cleared with antibiotics and standard
physiotherapy, iii) no antibiotic treatment response, and iv) totalFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 3serum IgE level <200 kU/L. In two patients, diagnosis of
pneumonia was postulated due to repeatedly positive sputum
cultures for Af combined with typical radiographic features.
Subjects were excluded if they met any of the following
criteria: i) intake of systemic glucocorticoids >5 days for ABPA
diagnosis and/or antifungal therapy >5 days within the last 4
weeks; ii) failure to provide informed consent. Patients on
standard therapy for Af diseases in CF (corticosteroid therapy
and/or antifungal treatment) were excluded to enable a clear
diagnosis and follow up examination after therapy.
For the available follow up measurements of Gm3, data >30
and <180 days after diagnosis and initiation of therapy were
included if the patients were stable at that time and did not meet
the diagnostic criteria for Af disease.
Af-Specific IgG (Gm3)
Af-specific IgG (Gm3) concentration was measured in our
routine laboratory by the commercial ImmunoCAP system
(Phadia, Thermo Fisher Scientific, USA), which uses
automated fluorescent enzyme immunoassay (FEIA)
technology. The m3 antigen is a crude extract from whole Af
conidia and mycelia. According to manufacturer data, the
reference value is <39 mg/L.
Statistical Analysis
Median and ranges were calculated for metrical variables.
Distribution of data was assessed with Shapiro–Wilk test for
normal distribution. For comparison of two groups t test or Mann–
Whitney test was applied as appropriate. Comparison of more than
two groups with normally distributed data sets was performed with
one-way ANOVA including Tukey´s multiple comparison test. Not
normally distributed data were analyzed by Kruskal Wallis test.
Frequency and percentage were used for categorical variables.
Associations of categorical variables were analyzed using chi-square
test. Cut-off value determination for IgGm3 was based on receiver
operating characteristic (ROC) analysis. A P value < 0.05 was
accepted to indicate statistical significance. Data analysis were
performed with GraphPad Prism version 8 (GraphPad Software).RESULTS
Baseline Characteristics
One hundred nine sera of patients with CF were analyzed for Af
IgG (Gm3 ImmunoCAP), with 63 patients assigned to the
control group, 22 patients to the bronchitis group, 18 patients
to the ABPA group and six patients to the pneumonia group. The
median age of all participants was 26 years (range: 6–69 years).
The median BMI was 19.8 kg/m2, with the lowest BMI in the
pneumonia group (17.5 kg/m2). The median percent predicted
FEV1 was 54 (range: 16.0–133.1), with the highest median
percent predicted FEV1 in the ABPA group (60) and the
lowest median percent predicted FEV1 in the pneumonia
group (22, p < 0,01). 24.8% of the patients had diabetes, with
the highest proportion in the pneumonia group (66.7%, no
statistical significance). The mean total IgG was 13.2 kU/L and
was markedly higher in the pneumonia group (16.3 kU/L, noJanuary 2021 | Volume 10 | Article 602836
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documented in 85.3% of all patients (control group 84.1%,
bronchitis 90.9%, ABPA and pneumonia each 83.3%, no
statistical significance). Detection of other fungal pathogens
was documented in 11% of all patients (22.7% bronchitis, 5.6%
ABPA, 0% pneumonia, no statistical significance) (see Table 1).
Af-Specific IgG (Gm3) Results
Median Gm3 for the control group was 48.9 mg/L ± 40.15 (2.7 -
>200 mg/L), for the bronchitis group 51.2 mg/L ± 38.6 (18.2 -
145 mg/L), for the ABPA group 97.5 mg/L ± 56,34 (24.2 - >200
mg/L), and for the pneumonia group 95.3 mg/L ± 22.5 (78.2 -
140 mg/L, p < 0.01, (see Figure 1).
A statistically significant difference was found between
median Gm3 of control vs. ABPA group (p < 0.05), and
between median Gm3 of control vs Af pneumonia group (p <
0.05). No significant difference was found between median Gm3
of control vs. bronchitis group (see Figure 1).
In the Af bronchitis and ABPA group, several patients did not
meet the manufacturer’s cut-off value of >39 mg/L: in the
bronchitis group, 31.8% (n=7) patients had Gm3 levels below
the cutoff, and in the ABPA group, 22.2% (n=4) patients had
Gm3 levels below the cutoff. In contrast, in the control group, a
majority of 58.7% (n=37) patients had Gm3 levels above the
cutoff. In the Af pneumonia group, all patients had Gm3 levels
above the manufacturer`s cut-off of >39 mg/L. (see Figure 1).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4Follow-Up Gm3
Twenty-one patients could be enrolled for a follow-up
examination. In the Af disease groups, it was assessed between
30 and 180 days after diagnosis. For the control group, meanTABLE 1 | Clinical characteristics of included patients.
*Variable Total Control Bronchitis ABPA Pneumonia P-value
Number of patients, n 109 63 22 18 6
Age, years, median (range) 26.0 (6–69) 27.0 (6–69) 26.0 (8.0–57.0) 21.5 (9.0–49.0) 30.5 (15.0–43.0) ns
Female sex, n (%) 62 (56.9%) 37 (58.7%) 14 (63.6%) 9 (50.0%) 2 (33.3%) ns
CFTR dF508 homozygous, n (%) 49 (45.0%) 26 (41.3%) 12 (54.5%) 8 (44.4%) 3 (50.0) ns
BMI, kg/m2, median (range) 19.8 (12.4–34.2) 20.2 (12.4–34.2) 20.2 (14.5–29.5) 18.8 (14.6–26.9) 17.5 (15.3–23.5) ns
Percent-predicted FEV1, median
(range)
54.0 (16.0–133.1) 60.0 (17.0–133.1) 41.0 (16.3–96.6) 60.0 (27.0–90.0) 22.0 (16.0–57.0) <0.01
Diabetes, n (%) 27 (24.8%) 12 (19.1%) 6 (27.3%) 5 (27.8%) 4 (66.7%)00 ns
Pancreatic insufficiency, n (%) 100 (91.7%) 57 (90.5%) 20 (90.9%) 17 (94.4%) 6 (100%) ns
Total IgG, kU/L, median (range) 13.2 (2.0–73.0) 13.2 (6.0–73.0) 12.3 (2.0–21.9) 13.6 (6.2–25.2) 16.3 (13.0–22.0) ns
Gm3, mg/L, median (range) 60.0 (3.0–200) 48.9 (2.7–200) 51.2 (18.2–145) 97.5 (24.2–200) 95.3 (78.2–140) <0.01
Gm3 > 39 mg/L,
n (%)
72 (66,1) 37 (58,7) 15 (68,2) 14 (77,8) 6 (100)
Total IgE, kU/L, median (range) 34.5 (2.0–4359) 26.5 (2.5–199) 30.2 (2.1–262) 1048 (344–4359) 44.4 (2.0–84.5) <0.01
Aspergillus specific IgE, kU/L,
median (range)
0.1 (0.1–51.7) 0.1 (0.1–0.1) 0.1 (0.1–3.2) 25.7 (10.8–51.7) 0.1 (0.1–1.0) <0.01




8 (7.3%) 0 (0%) 2 (9.1%) 5 (27.8%) 1 (16.7%) <0.01
Chronic Pseudomonas
aeruginosa, n (%)
71 (65.1%) 37 (58.7%) 17 (77.3%) 13 (72.2%) 4 (66.7%) ns
Aspergillus fumigatus positive
sputum, n (%)
45 (41.3%) 21 (33.3%) 17 (77.3%) 5 (27.8%) 2 (33.3%) <0.01
Aspergillus PCR positive, n (%),
n (%)
60 (55.0%) 30 (47.6%) 16 (72.7%) 12 (66.7%) 2 (33.3%) ns
Candida spp. positive sputum,
n (%)
93 (85.3%) 53 (84.1%) 20 (90.9%) 15 (83.3%) 5 (83.3%) ns
Detection of other fungal
pathogens*, n (%)
12 (11.0%) 6 (9.5%) 5 (22.7%) 1 (5.6%) 0 (0%) nsJanuary 2021 | Volume 10 | Article*Except Candida and Aspergillus species.FIGURE 1 | Gm3 (mg/L) for control group, Af bronchitis group, ABPA group
and Af pneumonia group before treatment. Adjusted p-values: control vs.
bronchitis: ns, control vs. ABPA: p <0.05, control vs. pneumonia: p <0.05.
* represents the level of significance (p ≤ 0.05).602836
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difference of the control group was 1.6 mg/L. For the bronchitis
group, the mean Gm3 difference after initiation of therapy was
13.4 mg/L, and for the ABPA group, it was 12.6 mg/L (no
statistical significance). In both the bronchitis and ABPA group,
single patients showed a rise in Gm3 in the follow up (see
Figure 2).
Cut-Off Determination
To determinate a cut-off value, only CF control subjects (n = 63)
and CF patients with ABPA or pneumonia (n = 24) were
included. ROC curve analysis showed an area under the curve
of 0.7675 (95% Confidence Interval = 0.6524–0.88826, see Figure
3) A cut-off value of 78.05 mg/L for Gm3 was calculated to
discriminate controls and patients with ABPA/pneumonia with a
specificity (white square line) of 75% and a sensitivity (black
square line) of 74.6% (see Figure 4).DISCUSSION
In this study, we evaluated the utility of Af specific Gm3 for the
diagnosis of Af associated diseases in CF. Mean Gm3 levels
revealed a significant difference between control group vs. ABPA
and vs. pneumonia group, but not vs. bronchitis group. Af
specific IgG may therefore be a useful biomarker for acute
ABPA and Af pneumonia in cystic fibrosis, but not for Af
bronchitis in cystic fibrosis.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5However, we also found a wide distribution of Gm3 in the
control, bronchitis and ABPA group. Thus, for the diagnosis of
ABPA and Af pneumonia in CF, Gm3 should only be interpreted
alongside other biomarkers.
Interestingly, a significant proportion of the Gm3 of our
control group exceeded the manufacturer`s cut-off-level of 39
mg/L. Due to the high exposure of the CF lung to respiratory
pathogens, the immune response in CF—here in the form of
Gm3—may fundamentally differ from that of healthy individuals.
Specific cut-offs may therefore be required in CF to describe
pathogen-mediated conditions. Positive and even high titers ofA B
DC
FIGURE 2 | Gm3 follow-up measurements for (A) control group, (B) Af bronchitis group, (C) ABPA group and (D) Af pneumonia group, for each group at time of
diagnosis (Day 1) and after treatment (Day 1 +x), for control group at any two consecutive times. Adjusted p-values: no statistical significance.FIGURE 3 | ROC curve analysis showing the performance of Gm3 for
distinguishing control group from ABPA/Af pneumonia group.January 2021 | Volume 10 | Article 602836
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other hand, the pathogenic impact and the need for treatment of
chronic colonization with Af in CF is still under discussion. In our
cohort, 33% of the control group patients had Af positive sputum
(see Table 1). There could be cases of bronchitis in the control
group that did not meet the definition of bronchitis. Another
reason for high Gm3 levels in the control group may be cross
reactivity to other fungi colonizing the respiratory tract in CF, as
m3 is the crude Af antigen and shows cross reactivities to other
opportunistic fungi (Fukutomi et al., 2016). In our cohort 85.3%
were co-colonized with Candida spp. and 11% with other fungi
(see Table 1). If this problem could be overcome by using
recombinant antigens, is unclear, because so far, no investigation
has been performed under this aspect. The studies conducted with
recombinant antigens to date show vastly different results
(Nikolaizik et al., 1995; Kurup, 2005; Fricker-Hidalgo et al.,
2010; Alghamdi et al., 2019). Finally, in some patients in the
cohort of acute Af diseases, Gm3 exceeds the measurement range
of 200 mg/L. Quantification above 200 mg/L could therefore
improve sensitivity and specificity.
The non-significant difference in median Gm3 levels between
control and bronchitis group could be explained by a
predominantly endobronchial host-pathogen interaction in Af
bronchitis, which may less likely lead to IgG production than in
the more invasive forms of aspergillosis. This may also explain
why a significant proportion of the bronchitis group had Gm3
levels below the manufacturer`s cut-off. On the other hand, also a
small but still significant proportion of the ABPA group had
Gm3 levels below the manufacturer`s cut-off, which may be due
to a predominant Type 1 hypersensitivity reaction in these cases.
Our results of a Gm3 cut-off-level of 78.05 mg/L with a
sensitivity of 75% and a specificity of 74.6% in Af pneumonia and
ABPA in CF differ substantially from those found in other
populations. Agarwal et al. examined Af specific Gm3 in
asthmatic patients with ABPA and Af sensitization without
ABPA and found a sensitivity of 88% and specificity of 100%
when using a cut-off level of 26.9 mg/L ImmunoCAP Gm3
(Agarwal et al., 2017). In chronic pulmonary aspergillosis in
non-CF-patients, Sehgal et al. found a sensitivity and specificity
of 95.6% and 100% using a Gm3 cut-off of 27.3 mg/L (SehgalFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 6et al., 2018). For simple aspergilloma in pulmonary tuberculosis
patients, the same working group found a sensitivity of 63.5%
and a specificity of 98.3% using a cut-off of 27.3 mg/L. However,
the Gm3 cut-off-level is still under discussion, as a recent
multicentric study found a median Gm3 of 21.3 mg/L and a
90% quantile for Gm3 of 78 mg/L in a population of 121 healthy
donors (Raulf et al., 2019). The working group suggested that
IgG values higher than at least 90% of the healthy donor group
indicate elevated levels, which is more consistent with our
findings of a cut-off-level of 78.05 mg/L.
Our follow-up data, where some patients showed a rise in
Gm3 at a second point of time after diagnosis are consistent
with the data of Agarwal et al. in asthmatic patients with ABPA,
who observed an increase of Gm3 in 23.1% of the patients and
a decrease in 23.1% (Agarwal et al., 2017). However,
immunoglobulins are often maintained long-time following
antigen contact, and, so far, no longitudinal data exist for titer
progression of Gm3. Considering the small number of cases in
our cohort, no statement can be made if and after what time Gm3
is suitable as a follow-up marker. Due to the low prevalence of Af
diseases in CF, the suitability of Gm3 as a screening and outcome
parameter should be investigated in a multicenter study.
CONCLUSION
Af-specific IgG may be a useful biomarker for acute ABPA
and Af pneumonia, but not for Af bronchitis in CF. However,
due to the large interindividual variability of Gm3, it should only
be interpreted alongside other biomarkers. Therefore, due to its
broad availability, it could be suitable as a biomarker for ABPA
and Af pneumonia in CF, if the results can be supported by a
larger multicenter cohort. Standardized, longitudinal studies and
a better knowledge of underlying immunological mechanisms
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